

Arizona TPOXX Request Process for Healthcare Providers



Clinician diagnosis of confirmed or suspected mpox.



Review [EA-IND eligibility](#) to identify if patient is eligible for tecovirimat (tppoxx).

If eligible, contact Arizona Department of Health Services (ADHS) at **602-364-3676** or PCC **480-303-1191** (If afterhours).

Be prepared to provide client information to establish [EA-IND eligibility](#). Expect to receive a call from ADHS medical personnel to confirm eligibility prior to drug dispensing.



If ADHS does not have supply, providers will be routed to CDC IND Protocol: Providers are responsible for completing required electronic forms through the [TPOXX IND Online Registry](#).

1. FDA Form 1572 - Only one per facility for all TPOXX prescribed. Return to CDC **within 7 calendar days** of starting treatment.
2. CDC Informed Consent Form ([Eng/ Span](#)) - Obtain **PRIOR** to treatment.



Upon confirmation of eligibility **AND** ADHS medical personnel approval, APDIS will direct TPOXX to be dispensed to the provider either from the Arizona State Public Health Laboratory (ASPHL) or from a prepositioned inventory.



Patients treated and monitored for duration of treatment.
Follow-up appointments should be on/around days 7 & 14 of treatment



Provider is responsible for completing remaining required EA-IND forms and returning them to CDC through the [TPOXX IND Online Registry](#) or via email (regaffairs@cdc.gov)

- CDC Patient Intake Form: Baseline assessment PRIOR to starting TPOXX. Submit **within 7 days** of treatment initiation.
- CDC Clinical Outcome Form: Progress and outcome information post treatment.
- [MedWatch Form](#): Report serious adverse events within 72 hours of awareness or sooner, if possible.

***Current as of 2/12/2026. Processes are subject to change.**